Shionogi & Co Ltd 2013 AR2
The report highlights Shionogi's performance and strategic progress during fiscal 2012, marking the halfway point of its Third Medium-Term Business Plan. The company achieved record operating income of 58.8 billion yen, driven by strong domestic sales of its eight strategic products and stabilized US operations. Key milestones included obtaining US FDA approval for Osphena, a treatment for postmenopausal vulvar and vaginal atrophy, and submitting regulatory filings for the anti-HIV agent dolutegravir in the US, EU, and Canada. Additionally, Shionogi restructured its global supply chain and production organizations, and advanced its environmental initiatives, reducing CO2 emissions by 6.8% compared to its benchmark year.
Company: Shionogi & Co Ltd
Sector: Health Care
Country: Japan
Year: 2013
Type: AR2
Pages: 78
Shionogi & Co Ltd
Annual Report
The report highlights Shionogi's performance and strategic progress during fiscal 2012, marking the halfway point of its Third Medium-Term Business Plan. The company achieved record operating income of 58.8 billion yen, driven by strong domestic sales of its eight strategic products and stabilized US operations. Key milestones included obtaining US FDA approval for Osphena, a treatment for postmenopausal vulvar and vaginal atrophy, and submitting regulatory filings for the anti-HIV agent dolutegravir in the US, EU, and Canada. Additionally, Shionogi restructured its global supply chain and production organizations, and advanced its environmental initiatives, reducing CO2 emissions by 6.8% compared to its benchmark year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Apr 1, 2012 - Mar 31, 2013
Fiscal Year
2012
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Total Waste
Employees